Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) had its price target boosted by Argus from $71.46 to $175.00 in a research report report published on Tuesday. They currently have a buy rating on the pharmaceutical company’s stock.

Several other equities research analysts have also commented on the company. Vetr upgraded Vertex Pharmaceuticals from a buy rating to a strong-buy rating and set a $181.00 price target for the company in a research note on Monday, July 31st. TheStreet lowered Vertex Pharmaceuticals from a b- rating to a c+ rating in a research note on Wednesday, July 26th. BMO Capital Markets reiterated an outperform rating and issued a $182.00 target price (up previously from $180.00) on shares of Vertex Pharmaceuticals in a research note on Thursday, July 27th. Oppenheimer Holdings, Inc. increased their target price on Vertex Pharmaceuticals from $150.00 to $175.00 and gave the company an outperform rating in a research note on Thursday, July 27th. Finally, J P Morgan Chase & Co set a $184.00 target price on Vertex Pharmaceuticals and gave the company a buy rating in a research note on Thursday, July 27th. Five analysts have rated the stock with a hold rating, twenty-two have assigned a buy rating and one has assigned a strong buy rating to the company. Vertex Pharmaceuticals has a consensus rating of Buy and an average price target of $162.88.

Vertex Pharmaceuticals (NASDAQ VRTX) traded up 0.33% during trading on Tuesday, reaching $154.54. The company’s stock had a trading volume of 807,795 shares. The company’s 50-day moving average is $137.73 and its 200-day moving average is $111.96. The company has a market capitalization of $38.96 billion, a P/E ratio of 148.45 and a beta of 1.77. Vertex Pharmaceuticals has a 1-year low of $71.46 and a 1-year high of $167.85.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.39 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.06 by $0.33. The company had revenue of $544.10 million during the quarter, compared to analyst estimates of $489.95 million. Vertex Pharmaceuticals had a return on equity of 4.64% and a net margin of 12.05%. The firm’s revenue was up 26.1% on a year-over-year basis. During the same period in the prior year, the firm posted $0.24 earnings per share. Equities analysts anticipate that Vertex Pharmaceuticals will post $1.59 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Argus Raises Vertex Pharmaceuticals Incorporated (VRTX) Price Target to $175.00” was first posted by Daily Political and is the property of of Daily Political. If you are accessing this piece on another publication, it was copied illegally and republished in violation of international copyright laws. The correct version of this piece can be viewed at https://www.dailypolitical.com/2017/08/05/argus-raises-vertex-pharmaceuticals-incorporated-vrtx-price-target-to-175-00.html.

In related news, EVP Stuart A. Arbuckle sold 70,969 shares of Vertex Pharmaceuticals stock in a transaction on Friday, June 2nd. The stock was sold at an average price of $128.06, for a total transaction of $9,088,290.14. Following the completion of the sale, the executive vice president now owns 145,061 shares of the company’s stock, valued at $18,576,511.66. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Jeffrey M. Leiden sold 147,101 shares of Vertex Pharmaceuticals stock in a transaction on Friday, June 2nd. The shares were sold at an average price of $129.50, for a total value of $19,049,579.50. Following the sale, the chief executive officer now directly owns 312,142 shares of the company’s stock, valued at approximately $40,422,389. The disclosure for this sale can be found here. In the last ninety days, insiders sold 745,503 shares of company stock valued at $112,220,787. 1.80% of the stock is currently owned by insiders.

A number of hedge funds have recently added to or reduced their stakes in VRTX. Guardian Life Insurance Co. of America boosted its stake in Vertex Pharmaceuticals by 0.6% in the first quarter. Guardian Life Insurance Co. of America now owns 956 shares of the pharmaceutical company’s stock worth $105,000 after buying an additional 6 shares during the last quarter. Elk Creek Partners LLC boosted its stake in Vertex Pharmaceuticals by 0.3% in the first quarter. Elk Creek Partners LLC now owns 3,120 shares of the pharmaceutical company’s stock worth $341,000 after buying an additional 10 shares during the last quarter. Sowell Financial Services LLC boosted its stake in Vertex Pharmaceuticals by 0.8% in the first quarter. Sowell Financial Services LLC now owns 2,762 shares of the pharmaceutical company’s stock worth $325,000 after buying an additional 23 shares during the last quarter. Capital Investment Advisory Services LLC boosted its stake in Vertex Pharmaceuticals by 0.4% in the first quarter. Capital Investment Advisory Services LLC now owns 6,463 shares of the pharmaceutical company’s stock worth $707,000 after buying an additional 25 shares during the last quarter. Finally, First Manhattan Co. boosted its stake in Vertex Pharmaceuticals by 1.3% in the first quarter. First Manhattan Co. now owns 2,356 shares of the pharmaceutical company’s stock worth $205,000 after buying an additional 31 shares during the last quarter. 94.37% of the stock is owned by hedge funds and other institutional investors.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Analyst Recommendations for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.